Nirogacestat in Ovarian Granulosa Cell Tumors

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

August 30, 2022

Primary Completion Date

July 31, 2026

Study Completion Date

December 31, 2027

Conditions
Ovarian Granulosa-Stromal TumorOvarian Granulosa Cell TumorOvarian Cancer
Interventions
DRUG

Nirogacestat

nirogacestat oral tablet

Trial Locations (21)

10032

Columbia University Medical Center, New York

10065

Memorial Sloan Kettering Cancer Institute, New York

21204

Greater Baltimore Medical Center, Baltimore

32804

AdventHealth Orlando, Orlando

32806

Orlando Health Cancer Institute, Orlando

33612

H. Lee Moffitt Cancer Center and Research Institute, Tampa

45429

Women's Cancer Center at Kettering, Kettering

53226

Froedtert and Medical College of Wisconsin, Milwaukee

63141

David C. Pratt Cancer Center, St Louis

70433

Women's Cancer Care, Covington

73104

OU Health Stephenson Cancer Center, Oklahoma City

87102

University of New Mexico Comprehensive Cancer Center, Albuquerque

90033

USC/Norris Comprehensive Cancer Center, Los Angeles

90095

UCLA-JCCC Dept. of OBGYN - Women's Health Clinical Research Unit, Los Angeles

98109

UW/Fred Hutch Cancer Center, Seattle

02215

Dana-Farber Cancer Institute, Boston

T6G 1Z2

Cross Cancer Institute, Edmonton

15-027

Maria Sklodowska-Curie Bialystok Oncology Center, Bialystok

30-348

Jagiellonian Innovation Centre Clinical Research Centre, Krakow

60-569

University Teaching Hospital Poznan, Department of Oncological Gynaecology, Poznan

02-781

Maria Sklodowska-Curie National Institute of Oncology-National Research Institute, Clinic of Oncological Gynecology, Warsaw

All Listed Sponsors
lead

SpringWorks Therapeutics, Inc.

INDUSTRY